{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:13:23Z","timestamp":1762528403947,"version":"build-2065373602"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40256-025-00744-x","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T06:19:10Z","timestamp":1753597150000},"page":"779-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overview of Systematic Reviews on Treatments for Pulmonary Arterial Hypertension: Assessing Methodological Quality and Mapping Evidence Gaps"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5162-313X","authenticated-orcid":false,"given":"Ana Paula Oliveira","family":"Vilela","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2188-9967","authenticated-orcid":false,"given":"Fl\u00e1via","family":"Deffert","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"issue":"4","key":"744_CR1","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1021\/acsptsci.0c00048","volume":"3","author":"M Spaczy\u0144ska","year":"2020","unstructured":"Spaczy\u0144ska M, Rocha SF, Oliver E. Pharmacology of pulmonary arterial hypertension: an overview of current and emerging therapies. ACS Pharmacol Transl Sci. 2020;3(4):598\u2013612. https:\/\/doi.org\/10.1021\/acsptsci.0c00048.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"744_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.01913-2018.","journal-title":"Eur Respir J"},{"issue":"4","key":"744_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0168-2022","volume":"18","author":"S Cullivan","year":"2022","unstructured":"Cullivan S, Higgins M, Gaine S. Diagnosis and management of pulmonary arterial hypertension. Breathe (Sheff). 2022;18(4): 220168. https:\/\/doi.org\/10.1183\/20734735.0168-2022.","journal-title":"Breathe (Sheff)"},{"key":"744_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","author":"M Humbert","year":"2023","unstructured":"Humbert M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023. https:\/\/doi.org\/10.1183\/13993003.00879-2022.","journal-title":"Eur Respir J"},{"key":"744_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biocel.2018.08.015","volume":"104","author":"A Bourgeois","year":"2018","unstructured":"Bourgeois A, et al. Pulmonary arterial hypertension: new pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018;104:9\u201313. https:\/\/doi.org\/10.1016\/j.biocel.2018.08.015.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"744_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","volume":"155","author":"JR Klinger","year":"2019","unstructured":"Klinger JR, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565\u201386. https:\/\/doi.org\/10.1016\/j.chest.2018.11.030.","journal-title":"Chest"},{"key":"744_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065850","author":"AJ Shah","year":"2023","unstructured":"Shah AJ, et al. New drugs and therapies in pulmonary arterial hypertension. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065850.","journal-title":"Int J Mol Sci"},{"issue":"3 Suppl","key":"744_CR8","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.37765\/ajmc.2021.88609","volume":"27","author":"DJ Levine","year":"2021","unstructured":"Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care. 2021;27(3 Suppl):S35\u201341. https:\/\/doi.org\/10.37765\/ajmc.2021.88609.","journal-title":"Am J Manag Care"},{"issue":"1","key":"744_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bph.15016","volume":"178","author":"N Sommer","year":"2021","unstructured":"Sommer N, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178(1):6\u201330. https:\/\/doi.org\/10.1111\/bph.15016.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"744_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jfma.2021.01.017","volume":"120","author":"CC Hung","year":"2021","unstructured":"Hung CC, Cheng CC, Huang WC. 2018 TSOC guideline focused updated on diagnosis and treatment of pulmonary arterial hypertension. J Formosan Med Assoc Taiwan yi zhi. 2021;120(7):1541\u20132. https:\/\/doi.org\/10.1016\/j.jfma.2021.01.017.","journal-title":"J Formosan Med Assoc Taiwan yi zhi"},{"issue":"9","key":"744_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.healun.2012.06.002","volume":"31","author":"JC Fang","year":"2012","unstructured":"Fang JC, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult\u2014a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913\u201333. https:\/\/doi.org\/10.1016\/j.healun.2012.06.002.","journal-title":"J Heart Lung Transplant"},{"issue":"23","key":"744_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.21037\/atm.2019.11.19","volume":"7","author":"F Chen","year":"2019","unstructured":"Chen F, et al. Efficacy and safety of statin therapy in pulmonary hypertension: a systematic review and meta-analysis. Ann Transl Med. 2019;7(23):786. https:\/\/doi.org\/10.21037\/atm.2019.11.19.","journal-title":"Ann Transl Med"},{"issue":"3","key":"744_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1086\/687304","volume":"6","author":"V Anand","year":"2016","unstructured":"Anand V, et al. A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension. Pulm Circ. 2016;6(3):295\u2013301. https:\/\/doi.org\/10.1086\/687304.","journal-title":"Pulm Circ"},{"issue":"5","key":"744_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1183\/09031936.06.00015206","volume":"28","author":"SR Johnson","year":"2006","unstructured":"Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006;28(5):999\u20131004. https:\/\/doi.org\/10.1183\/09031936.06.00015206.","journal-title":"Eur Respir J"},{"issue":"2","key":"744_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1378\/chest.14-0793","volume":"146","author":"DB Taichman","year":"2014","unstructured":"Taichman DB, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449\u201375. https:\/\/doi.org\/10.1378\/chest.14-0793.","journal-title":"Chest"},{"issue":"4","key":"744_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196644","volume":"13","author":"FS Tonin","year":"2018","unstructured":"Tonin FS, et al. Mapping the characteristics of network meta-analyses on drug therapy: a systematic review. PLoS ONE. 2018;13(4): e0196644. https:\/\/doi.org\/10.1371\/journal.pone.0196644.","journal-title":"PLoS ONE"},{"issue":"7","key":"744_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/circresaha.117.312579","volume":"122","author":"S Provencher","year":"2018","unstructured":"Provencher S, et al. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational research. Circ Res. 2018;122(7):1021\u201332. https:\/\/doi.org\/10.1161\/circresaha.117.312579.","journal-title":"Circ Res"},{"issue":"4","key":"744_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1125","volume":"16","author":"H White","year":"2020","unstructured":"White H, et al. Guidance for producing a Campbell evidence and gap map. Campbell Syst Rev. 2020;16(4): e1125. https:\/\/doi.org\/10.1002\/cl2.1125.","journal-title":"Campbell Syst Rev"},{"issue":"1","key":"744_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13643-023-02178-5","volume":"12","author":"F Campbell","year":"2023","unstructured":"Campbell F, et al. Mapping reviews, scoping reviews, and evidence and gap maps (EGMs): the same but different\u2014the \u201cBig Picture\u201d review family. Syst Rev. 2023;12(1):45. https:\/\/doi.org\/10.1186\/s13643-023-02178-5.","journal-title":"Syst Rev"},{"key":"744_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jclinepi.2016.05.015","volume":"79","author":"B Snilstveit","year":"2016","unstructured":"Snilstveit B, et al. Evidence & Gap Maps: a tool for promoting evidence informed policy and strategic research agendas. J Clin Epidemiol. 2016;79:120\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.05.015.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"744_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/ije\/dyy197","volume":"48","author":"FS Tonin","year":"2019","unstructured":"Tonin FS, et al. Methodological quality assessment of network meta-analysis of drug interventions: implications from a systematic review. Int J Epidemiol. 2019;48(2):620\u201332. https:\/\/doi.org\/10.1093\/ije\/dyy197.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"744_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/1468-0009.12210","volume":"94","author":"JP Ioannidis","year":"2016","unstructured":"Ioannidis JP. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q. 2016;94(3):485\u2013514. https:\/\/doi.org\/10.1111\/1468-0009.12210.","journal-title":"Milbank Q"},{"issue":"3","key":"744_CR23","doi-asserted-by":"publisher","first-page":"339.e11","DOI":"10.1016\/j.amjmed.2015.10.009","volume":"129","author":"IB Riaz","year":"2016","unstructured":"Riaz IB, et al. Disorganized systematic reviews and meta-analyses: time to systematize the conduct and publication of these study overviews? Am J Med. 2016;129(3):339.e11-8. https:\/\/doi.org\/10.1016\/j.amjmed.2015.10.009.","journal-title":"Am J Med"},{"key":"744_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.924873","volume":"9","author":"J Santos-Gomes","year":"2022","unstructured":"Santos-Gomes J, et al. An overview of circulating pulmonary arterial hypertension biomarkers. Front Cardiovasc Med. 2022;9: 924873. https:\/\/doi.org\/10.3389\/fcvm.2022.924873.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"744_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/01.NURSE.0000795272.64847.1b","volume":"51","author":"GM O\u2019Leary","year":"2021","unstructured":"O\u2019Leary GM. Pulmonary arterial hypertension: an overview. Nursing. 2021;51(11):37\u201343. https:\/\/doi.org\/10.1097\/01.NURSE.0000795272.64847.1b.","journal-title":"Nursing"},{"key":"744_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2024.107374","volume":"155","author":"M D\u2019Alto","year":"2024","unstructured":"D\u2019Alto M, et al. Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC\/ERS 2022 guidelines. Vascul Pharmacol. 2024;155: 107374. https:\/\/doi.org\/10.1016\/j.vph.2024.107374.","journal-title":"Vascul Pharmacol"},{"key":"744_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijcard.2022.06.026","volume":"364","author":"CD Vizza","year":"2022","unstructured":"Vizza CD, et al. Gaps of evidence in pulmonary arterial hypertension. Int J Cardiol. 2022;364:119\u201323. https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.026.","journal-title":"Int J Cardiol"},{"key":"744_CR28","doi-asserted-by":"publisher","unstructured":"Institute JB. JBI Manual for evidence synthesis. https:\/\/doi.org\/10.46658\/JBIMES-20-01.","DOI":"10.46658\/JBIMES-20-01"},{"key":"744_CR29","doi-asserted-by":"publisher","unstructured":"Higgins JPT, et al. Front matter. In: Cochrane handbook for systematic reviews of interventions. 2019. pp. i\u2013xxviii. https:\/\/doi.org\/10.1002\/9781119536604.fmatter.","DOI":"10.1002\/9781119536604.fmatter"},{"key":"744_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"744_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"744_CR32","unstructured":"Reports JC. Clarivate. 2023. https:\/\/jcrclarivate.ez372.periodicos.capes.gov.br\/jcr\/home."},{"key":"744_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"issue":"1","key":"744_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-023-12090-6","volume":"271","author":"KZA Domingues","year":"2024","unstructured":"Domingues KZA, et al. Systematic review and evidence gap mapping of biomarkers associated with neurological manifestations in patients with COVID-19. J Neurol. 2024;271(1):1\u201323. https:\/\/doi.org\/10.1007\/s00415-023-12090-6.","journal-title":"J Neurol"},{"issue":"3","key":"744_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000334431","volume":"120","author":"Y Bai","year":"2011","unstructured":"Bai Y, et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology. 2011;120(3):157\u201365. https:\/\/doi.org\/10.1159\/000334431.","journal-title":"Cardiology"},{"key":"744_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102100","volume":"72","author":"M Chen","year":"2022","unstructured":"Chen M, et al. Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: a meta-analysis. Pulm Pharmacol Ther. 2022;72: 102100. https:\/\/doi.org\/10.1016\/j.pupt.2021.102100.","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"744_CR37","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.3892\/etm.2019.8142","volume":"18","author":"ZC Dang","year":"2019","unstructured":"Dang ZC, et al. A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension. Exp Ther Med. 2019;18(6):4740\u20136. https:\/\/doi.org\/10.3892\/etm.2019.8142.","journal-title":"Exp Ther Med"},{"key":"744_CR38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2147\/ppa.S133288","volume":"11","author":"XF Gao","year":"2017","unstructured":"Gao XF, et al. Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. Patient Prefer Adherence. 2017;11:871\u201385. https:\/\/doi.org\/10.2147\/ppa.S133288.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"744_CR39","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1253\/circj.cj-09-0971","volume":"74","author":"B He","year":"2010","unstructured":"He B, et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J. 2010;74(7):1458\u201364. https:\/\/doi.org\/10.1253\/circj.cj-09-0971.","journal-title":"Circ J"},{"key":"744_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pupt.2015.03.002","volume":"32","author":"CJ He","year":"2015","unstructured":"He CJ, et al. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: a meta-analysis focusing on 6MWD. Pulm Pharmacol Ther. 2015;32:24\u20138. https:\/\/doi.org\/10.1016\/j.pupt.2015.03.002.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"744_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1536\/ihj.15-459","volume":"57","author":"A Igarashi","year":"2016","unstructured":"Igarashi A, et al. Comparative effectiveness of oral medications for pulmonary arterial hypertension. Int Heart J. 2016;57(4):466\u201372. https:\/\/doi.org\/10.1536\/ihj.15-459.","journal-title":"Int Heart J"},{"issue":"4","key":"744_CR42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40256-018-00324-2","volume":"19","author":"H Kuang","year":"2019","unstructured":"Kuang H, et al. The efficacy and safety of aerosolized iloprost in pulmonary arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2019;19(4):393\u2013401. https:\/\/doi.org\/10.1007\/s40256-018-00324-2.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"744_CR43","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3904\/kjim.2013.28.6.701","volume":"28","author":"YH Lee","year":"2013","unstructured":"Lee YH, Song GG. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension. Korean J Intern Med. 2013;28(6):701\u20137. https:\/\/doi.org\/10.3904\/kjim.2013.28.6.701.","journal-title":"Korean J Intern Med"},{"key":"744_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.977110","volume":"9","author":"J Li","year":"2022","unstructured":"Li J, et al. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9: 977110. https:\/\/doi.org\/10.3389\/fcvm.2022.977110.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"744_CR45","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1185\/03007995.2013.802682","volume":"29","author":"T Li","year":"2013","unstructured":"Li T, et al. Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Curr Med Res Opin. 2013;29(8):889\u201399. https:\/\/doi.org\/10.1185\/03007995.2013.802682.","journal-title":"Curr Med Res Opin"},{"key":"744_CR46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fphar.2020.00400","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Li T. Combined methods (formal adjusted indirect comparison, meta-analysis and principal component analysis) comparisons of the safety and efficacy of ambrisentan, bosentan, and sildenafil in the patients with pulmonary arterial hypertension. Front Pharmacol. 2020;11:400. https:\/\/doi.org\/10.3389\/fphar.2020.00400.","journal-title":"Front Pharmacol"},{"key":"744_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2017.11.002","volume":"50","author":"H Lin","year":"2018","unstructured":"Lin H, et al. Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: a network meta-analysis. Pulm Pharmacol Ther. 2018;50:1\u201310. https:\/\/doi.org\/10.1016\/j.pupt.2017.11.002.","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"744_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.chest.2016.03.031","volume":"150","author":"HL Liu","year":"2016","unstructured":"Liu HL, et al. Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Chest. 2016;150(2):353\u201366. https:\/\/doi.org\/10.1016\/j.chest.2016.03.031.","journal-title":"Chest"},{"issue":"2","key":"744_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101466","volume":"48","author":"J Qin","year":"2023","unstructured":"Qin J, Wang G, Han D. Selexipag in patients with pulmonary hypertension: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2023;48(2): 101466. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101466.","journal-title":"Curr Probl Cardiol"},{"key":"744_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.817119","volume":"13","author":"P Wang","year":"2022","unstructured":"Wang P, et al. Additional use of prostacyclin analogs in patients with pulmonary arterial hypertension: a meta-analysis. Front Pharmacol. 2022;13: 817119. https:\/\/doi.org\/10.3389\/fphar.2022.817119.","journal-title":"Front Pharmacol"},{"issue":"1","key":"744_CR51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ahj.2015.04.003","volume":"170","author":"HD Zhang","year":"2015","unstructured":"Zhang HD, et al. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: a systematic review and meta-analysis. Am Heart J. 2015;170(1):96-103.e1-e14. https:\/\/doi.org\/10.1016\/j.ahj.2015.04.003.","journal-title":"Am Heart J"},{"issue":"5","key":"744_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.hlc.2016.08.005","volume":"26","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, et al. Efficacy and safety of statins for pulmonary hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2017;26(5):425\u201332. https:\/\/doi.org\/10.1016\/j.hlc.2016.08.005.","journal-title":"Heart Lung Circ"},{"issue":"3","key":"744_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/cdt.2019.03.02","volume":"9","author":"YJ Zhang","year":"2019","unstructured":"Zhang YJ, et al. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension. Cardiovasc Diagn Ther. 2019;9(3):239\u201349. https:\/\/doi.org\/10.21037\/cdt.2019.03.02.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"744_CR54","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/jcpt.13481","volume":"47","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, et al. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: a meta-analysis. J Clin Pharm Ther. 2022;47(2):146\u201356. https:\/\/doi.org\/10.1111\/jcpt.13481.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"744_CR55","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00059-018-4697-z","volume":"44","author":"R Zhao","year":"2019","unstructured":"Zhao R, Jiang Y. Influence of riociguat treatment on pulmonary arterial hypertension\u202f: a meta-analysis of randomized controlled trials. Herz. 2019;44(7):637\u201343. https:\/\/doi.org\/10.1007\/s00059-018-4697-z.","journal-title":"Herz"},{"issue":"4","key":"744_CR56","doi-asserted-by":"publisher","first-page":"204589401879818","DOI":"10.1177\/2045894018798183","volume":"8","author":"YG Zheng","year":"2018","unstructured":"Zheng YG, et al. Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials. Pulm Circ. 2018;8(4):2045894018798183. https:\/\/doi.org\/10.1177\/2045894018798183.","journal-title":"Pulm Circ"},{"issue":"1","key":"744_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00228-013-1583-8","volume":"70","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, et al. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. Eur J Clin Pharmacol. 2014;70(1):13\u201321. https:\/\/doi.org\/10.1007\/s00228-013-1583-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"744_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.915470","volume":"9","author":"HR Zhu","year":"2022","unstructured":"Zhu HR, et al. Effects of oral targeted treatments in pulmonary arterial hypertension: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9: 915470. https:\/\/doi.org\/10.3389\/fcvm.2022.915470.","journal-title":"Front Cardiovasc Med"},{"key":"744_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2022.102182","volume":"78","author":"P Wang","year":"2023","unstructured":"Wang P, et al. Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: a meta-analysis. Pulm Pharmacol Ther. 2023;78: 102182. https:\/\/doi.org\/10.1016\/j.pupt.2022.102182.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"744_CR60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.rmed.2014.01.003","volume":"108","author":"RC Wang","year":"2014","unstructured":"Wang RC, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med. 2014;108(3):531\u20137. https:\/\/doi.org\/10.1016\/j.rmed.2014.01.003.","journal-title":"Respir Med"},{"issue":"2","key":"744_CR61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.pupt.2014.08.005","volume":"29","author":"YG Zheng","year":"2014","unstructured":"Zheng YG, et al. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials. Pulm Pharmacol Ther. 2014;29(2):241\u20139. https:\/\/doi.org\/10.1016\/j.pupt.2014.08.005.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"744_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ame2.12347","volume":"7","author":"S Wang","year":"2024","unstructured":"Wang S, et al. Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: a systematic review and meta-analysis. Animal Model Exp Med. 2024;7(1):56\u201370. https:\/\/doi.org\/10.1002\/ame2.12347.","journal-title":"Animal Model Exp Med"},{"key":"744_CR63","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.hrtlng.2023.11.006","volume":"64","author":"R Zhou","year":"2024","unstructured":"Zhou R, et al. Efficacy and safety of iloprost in the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis. Heart Lung J Cardiopulm Acute Care. 2024;64:36\u201345. https:\/\/doi.org\/10.1016\/j.hrtlng.2023.11.006.","journal-title":"Heart Lung J Cardiopulm Acute Care"},{"key":"744_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1052546","author":"YY Liu","year":"2023","unstructured":"Liu YY, et al. Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: a systematic review and meta-analysis. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1052546.","journal-title":"Front Pharmacol"},{"issue":"5","key":"744_CR65","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1378\/chest.13-1864","volume":"145","author":"RR Coeytaux","year":"2014","unstructured":"Coeytaux RR, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014;145(5):1055\u201363. https:\/\/doi.org\/10.1378\/chest.13-1864.","journal-title":"Chest"},{"issue":"8","key":"744_CR66","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.amjcard.2011.06.021","volume":"108","author":"BD Fox","year":"2011","unstructured":"Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. 2011;108(8):1177\u201382. https:\/\/doi.org\/10.1016\/j.amjcard.2011.06.021.","journal-title":"Am J Cardiol"},{"issue":"1","key":"744_CR67","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.chest.2016.08.1461","volume":"151","author":"S Jain","year":"2017","unstructured":"Jain S, et al. Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. Chest. 2017;151(1):90\u2013105. https:\/\/doi.org\/10.1016\/j.chest.2016.08.1461.","journal-title":"Chest"},{"issue":"1","key":"744_CR68","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33363","volume":"15","author":"J Karedath","year":"2023","unstructured":"Karedath J, et al. Effect of phosphodiesterase-5 (PDE-5) inhibitors on clinical outcomes in patients with pulmonary hypertension: a meta-analysis of randomized control trials. Cureus. 2023;15(1): e33363. https:\/\/doi.org\/10.7759\/cureus.33363.","journal-title":"Cureus"},{"issue":"9","key":"744_CR69","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.118.004757","volume":"11","author":"MS Khan","year":"2018","unstructured":"Khan MS, et al. Is anticoagulation beneficial in pulmonary arterial hypertension? Circ Cardiovasc Qual Outcomes. 2018;11(9): e004757. https:\/\/doi.org\/10.1161\/circoutcomes.118.004757.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"744_CR70","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00408-016-9928-6","volume":"194","author":"M Kuntz","year":"2016","unstructured":"Kuntz M, Leiva-Juarez MM, Luthra S. Systematic review of randomized controlled trials of endothelin receptor antagonists for pulmonary arterial hypertension. Lung. 2016;194(5):723\u201332. https:\/\/doi.org\/10.1007\/s00408-016-9928-6.","journal-title":"Lung"},{"issue":"4","key":"744_CR71","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s2213-2600(16)00027-8","volume":"4","author":"AC Lajoie","year":"2016","unstructured":"Lajoie AC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291\u2013305. https:\/\/doi.org\/10.1016\/s2213-2600(16)00027-8.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"744_CR72","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/archinte.1997.00440270057005","volume":"157","author":"AS Malik","year":"1997","unstructured":"Malik AS, Warshafsky S, Lehrman S. Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. Arch Intern Med. 1997;157(6):621\u20135.","journal-title":"Arch Intern Med"},{"issue":"1","key":"744_CR73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1465-9921-11-12","volume":"11","author":"CJ Ryerson","year":"2010","unstructured":"Ryerson CJ, et al. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res. 2010;11(1):12. https:\/\/doi.org\/10.1186\/1465-9921-11-12.","journal-title":"Respir Res"},{"issue":"10","key":"744_CR74","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/j.1742-1241.2007.01545.x","volume":"61","author":"F Torres","year":"2007","unstructured":"Torres F. Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. Int J Clin Pract. 2007;61(10):1756\u201365. https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01545.x.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"744_CR75","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.hlc.2015.05.020","volume":"25","author":"B Badiani","year":"2016","unstructured":"Badiani B, Messori A. Targeted treatments for pulmonary arterial hypertension: interpreting outcomes by network meta-analysis. Heart Lung Circ. 2016;25(1):46\u201352. https:\/\/doi.org\/10.1016\/j.hlc.2015.05.020.","journal-title":"Heart Lung Circ"},{"key":"744_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2024.107280","volume":"154","author":"G Manzi","year":"2024","unstructured":"Manzi G, et al. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: a systematic review and network meta-analysis. Vascul Pharmacol. 2024;154: 107280. https:\/\/doi.org\/10.1016\/j.vph.2024.107280.","journal-title":"Vascul Pharmacol"},{"issue":"8","key":"744_CR77","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cjca.2014.04.016","volume":"30","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, et al. Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis. Can J Cardiol. 2014;30(8):879\u201387. https:\/\/doi.org\/10.1016\/j.cjca.2014.04.016.","journal-title":"Can J Cardiol"},{"issue":"49","key":"744_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13490","volume":"13","author":"YF Chen","year":"2009","unstructured":"Chen YF, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009;13(49):1\u2013320. https:\/\/doi.org\/10.3310\/hta13490.","journal-title":"Health Technol Assess"},{"issue":"1","key":"744_CR79","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.chest.2017.12.008","volume":"154","author":"C Khouri","year":"2018","unstructured":"Khouri C, et al. Comparative safety of drugs targeting the nitric oxide pathway in pulmonary hypertension: a mixed approach combining a meta-analysis of clinical trials and a disproportionality analysis from the World Health Organization pharmacovigilance database. Chest. 2018;154(1):136\u201347. https:\/\/doi.org\/10.1016\/j.chest.2017.12.008.","journal-title":"Chest"},{"issue":"4","key":"744_CR80","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","volume":"30","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8 N, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4):394\u2013403. https:\/\/doi.org\/10.1093\/eurheartj\/ehp022.","journal-title":"Eur Heart J"},{"issue":"1","key":"744_CR81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40256-022-00553-6","volume":"23","author":"S Qadus","year":"2023","unstructured":"Qadus S, et al. Adherence and discontinuation of disease-specific therapies for pulmonary arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2023;23(1):19\u201333. https:\/\/doi.org\/10.1007\/s40256-022-00553-6.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"744_CR82","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1060028019888760","volume":"54","author":"M Petrovi\u010d","year":"2020","unstructured":"Petrovi\u010d M, Locatelli I. A Bayesian network meta-analysis of add-on drug therapies specific for pulmonary arterial hypertension. Ann Pharmacother. 2020;54(5):423\u201333. https:\/\/doi.org\/10.1177\/1060028019888760.","journal-title":"Ann Pharmacother"},{"key":"744_CR83","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00313-2022","author":"IT Farmakis","year":"2022","unstructured":"Farmakis IT, et al. Haemodynamic effects of initial combination therapy in pulmonary arterial hypertension: a systematic review and meta-analysis. ERJ Open Res. 2022. https:\/\/doi.org\/10.1183\/23120541.00313-2022.","journal-title":"ERJ Open Res"},{"issue":"4","key":"744_CR84","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/jamapsychiatry.2017.0035","volume":"74","author":"JP Ioannidis","year":"2017","unstructured":"Ioannidis JP. Meta-analyses can be credible and useful: a new standard. JAMA Psychiat. 2017;74(4):311\u20132. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0035.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"744_CR85","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11096-016-0288-3","volume":"38","author":"K MacLure","year":"2016","unstructured":"MacLure K, Paudyal V, Stewart D. Reviewing the literature, how systematic is systematic? Int J Clin Pharm. 2016;38(3):685\u201394. https:\/\/doi.org\/10.1007\/s11096-016-0288-3.","journal-title":"Int J Clin Pharm"},{"key":"744_CR86","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jclinepi.2017.10.017","volume":"94","author":"MJ Page","year":"2018","unstructured":"Page MJ, et al. Reproducible research practices are underused in systematic reviews of biomedical interventions. J Clin Epidemiol. 2018;94:8\u201318. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.10.017.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"744_CR87","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.sapharm.2021.06.002","volume":"18","author":"AF Bonetti","year":"2022","unstructured":"Bonetti AF, et al. Methodological standards for conducting and reporting meta-analyses: ensuring the replicability of meta-analyses of pharmacist-led medication review. Res Social Adm Pharm. 2022;18(2):2259\u201368. https:\/\/doi.org\/10.1016\/j.sapharm.2021.06.002.","journal-title":"Res Social Adm Pharm"},{"key":"744_CR88","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-3-319-67144-4_12","volume":"1031","author":"S Day","year":"2017","unstructured":"Day S. Evidence-based medicine and rare diseases. Adv Exp Med Biol. 2017;1031:207\u201320. https:\/\/doi.org\/10.1007\/978-3-319-67144-4_12.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"744_CR89","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ejvs.2022.07.045","volume":"64","author":"CP Twine","year":"2022","unstructured":"Twine CP, Mani K. A brief guide to performing review and meta-analysis of rare diseases, procedures, and other low frequency pathology. Eur J Vasc Endovasc Surg. 2022;64(4):297\u20138. https:\/\/doi.org\/10.1016\/j.ejvs.2022.07.045.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"744_CR90","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.sapharm.2020.12.011","volume":"18","author":"AF Bonetti","year":"2022","unstructured":"Bonetti AF, et al. Methodological quality and risk of bias of meta-analyses of pharmacy services: a systematic review. Res Social Adm Pharm. 2022;18(3):2403\u20139. https:\/\/doi.org\/10.1016\/j.sapharm.2020.12.011.","journal-title":"Res Social Adm Pharm"},{"key":"744_CR91","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijcard.2023.05.036","volume":"386","author":"PG de Sousa","year":"2023","unstructured":"de Sousa PG, et al. Mapping the characteristics, methodological quality and standards of reporting of network meta-analyses on antithrombotic therapies: an overview. Int J Cardiol. 2023;386:125\u201333. https:\/\/doi.org\/10.1016\/j.ijcard.2023.05.036.","journal-title":"Int J Cardiol"},{"issue":"2","key":"744_CR92","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.Ccm.0000253394.15628.Fd","volume":"35","author":"A Delaney","year":"2007","unstructured":"Delaney A, et al. The quality of reports of critical care meta-analyses in the Cochrane Database of Systematic Reviews: an independent appraisal. Crit Care Med. 2007;35(2):589\u201394. https:\/\/doi.org\/10.1097\/01.Ccm.0000253394.15628.Fd.","journal-title":"Crit Care Med"},{"issue":"5","key":"744_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002028","volume":"13","author":"MJ Page","year":"2016","unstructured":"Page MJ, et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS Med. 2016;13(5): e1002028. https:\/\/doi.org\/10.1371\/journal.pmed.1002028.","journal-title":"PLoS Med"},{"issue":"2","key":"744_CR94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bjpt.2019.04.004","volume":"24","author":"MO Almeida","year":"2020","unstructured":"Almeida MO, et al. Overall confidence in the results of systematic reviews on exercise therapy for chronic low back pain: a cross-sectional analysis using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 tool. Braz J Phys Ther. 2020;24(2):103\u201317. https:\/\/doi.org\/10.1016\/j.bjpt.2019.04.004.","journal-title":"Braz J Phys Ther"},{"issue":"1","key":"744_CR95","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s13643-019-1191-5","volume":"8","author":"R Perry","year":"2019","unstructured":"Perry R, et al. An overview of systematic reviews of complementary and alternative therapies for infantile colic. Syst Rev. 2019;8(1):271. https:\/\/doi.org\/10.1186\/s13643-019-1191-5.","journal-title":"Syst Rev"},{"key":"744_CR96","doi-asserted-by":"publisher","first-page":"8620186","DOI":"10.1155\/2020\/8620186","volume":"2020","author":"SS Lin","year":"2020","unstructured":"Lin SS, et al. Efficacy and safety of oral chinese patent medicine combined with conventional therapy for heart failure: an overview of systematic reviews. Evid Based Complement Alternat Med. 2020;2020:8620186. https:\/\/doi.org\/10.1155\/2020\/8620186.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"744_CR97","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13643-017-0527-2","volume":"6","author":"K Pussegoda","year":"2017","unstructured":"Pussegoda K, et al. Systematic review adherence to methodological or reporting quality. Syst Rev. 2017;6(1):131. https:\/\/doi.org\/10.1186\/s13643-017-0527-2.","journal-title":"Syst Rev"},{"key":"744_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"744_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.10.026","volume":"165","author":"R Bojcic","year":"2024","unstructured":"Bojcic R, Todoric M, Puljak L. Most systematic reviews reporting adherence to AMSTAR 2 had critically low methodological quality: a cross-sectional meta-research study. J Clin Epidemiol. 2024;165: 111210. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.10.026.","journal-title":"J Clin Epidemiol"},{"issue":"18","key":"744_CR100","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.021367","volume":"10","author":"D Mahtta","year":"2021","unstructured":"Mahtta D, et al. Methodological rigor and temporal trends of cardiovascular medicine meta-analyses in highest-impact journals. J Am Heart Assoc. 2021;10(18): e021367. https:\/\/doi.org\/10.1161\/jaha.121.021367.","journal-title":"J Am Heart Assoc"},{"key":"744_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.671569","volume":"8","author":"AI Abushouk","year":"2021","unstructured":"Abushouk AI, et al. Quality assessment of published systematic reviews in high impact cardiology journals: revisiting the evidence pyramid. Front Cardiovasc Med. 2021;8: 671569. https:\/\/doi.org\/10.3389\/fcvm.2021.671569.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"744_CR102","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.mehy.2015.07.003","volume":"85","author":"GD Tebala","year":"2015","unstructured":"Tebala GD. What is the future of biomedical research? Med Hypotheses. 2015;85(4):488\u201390. https:\/\/doi.org\/10.1016\/j.mehy.2015.07.003.","journal-title":"Med Hypotheses"},{"issue":"1","key":"744_CR103","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13643-022-02029-9","volume":"11","author":"L Li","year":"2022","unstructured":"Li L, et al. AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals. Syst Rev. 2022;11(1):147. https:\/\/doi.org\/10.1186\/s13643-022-02029-9.","journal-title":"Syst Rev"},{"key":"744_CR104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2046-4053-1-7","volume":"1","author":"L Stewart","year":"2012","unstructured":"Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. Syst Rev. 2012;1:7. https:\/\/doi.org\/10.1186\/2046-4053-1-7.","journal-title":"Syst Rev"},{"key":"744_CR105","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2. https:\/\/doi.org\/10.1186\/2046-4053-1-2.","journal-title":"Syst Rev"},{"issue":"3","key":"744_CR106","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.ebd.6400602","volume":"9","author":"D Richards","year":"2008","unstructured":"Richards D. Handsearching still a valuable element of the systematic review. Evid Based Dent. 2008;9(3):85. https:\/\/doi.org\/10.1038\/sj.ebd.6400602.","journal-title":"Evid Based Dent"},{"issue":"4","key":"744_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001987","volume":"13","author":"A Bilandzic","year":"2016","unstructured":"Bilandzic A, et al. Risk of bias in systematic reviews of non-randomized studies of adverse cardiovascular effects of thiazolidinediones and cyclooxygenase-2 inhibitors: application of a new cochrane risk of bias tool. PLoS Med. 2016;13(4): e1001987. https:\/\/doi.org\/10.1371\/journal.pmed.1001987.","journal-title":"PLoS Med"},{"key":"744_CR108","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.maturitas.2016.06.007","volume":"91","author":"E Gargon","year":"2016","unstructured":"Gargon E. The COMET (core outcome measures in effectiveness trials) initiative. Maturitas. 2016;91:91\u20132. https:\/\/doi.org\/10.1016\/j.maturitas.2016.06.007.","journal-title":"Maturitas"},{"issue":"8","key":"744_CR109","first-page":"919","volume":"132","author":"GH Guyatt","year":"1985","unstructured":"Guyatt GH, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919\u201323.","journal-title":"Can Med Assoc J"},{"issue":"4","key":"744_CR110","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/s0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780\u20138. https:\/\/doi.org\/10.1016\/s0735-1097(02)02012-0.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"744_CR111","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","volume":"161","author":"S Miyamoto","year":"2000","unstructured":"Miyamoto S, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2):487\u201392. https:\/\/doi.org\/10.1164\/ajrccm.161.2.9906015.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12 Suppl S","key":"744_CR112","doi-asserted-by":"publisher","first-page":"48s","DOI":"10.1016\/j.jacc.2004.02.010","volume":"43","author":"MM Hoeper","year":"2004","unstructured":"Hoeper MM, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004;43(12 Suppl S):48s\u201355s. https:\/\/doi.org\/10.1016\/j.jacc.2004.02.010.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"744_CR113","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ahj.2015.06.010","volume":"170","author":"KS Parikh","year":"2015","unstructured":"Parikh KS, et al. Use of outcome measures in pulmonary hypertension clinical trials. Am Heart J. 2015;170(3):419-29.e3. https:\/\/doi.org\/10.1016\/j.ahj.2015.06.010.","journal-title":"Am Heart J"},{"key":"744_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4501","volume":"347","author":"KC Siontis","year":"2013","unstructured":"Siontis KC, Hernandez-Boussard T, Ioannidis JP. Overlapping meta-analyses on the same topic: survey of published studies. BMJ. 2013;347: f4501. https:\/\/doi.org\/10.1136\/bmj.f4501.","journal-title":"BMJ"},{"issue":"1","key":"744_CR115","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13643-023-02227-z","volume":"12","author":"M Hoerold","year":"2023","unstructured":"Hoerold M, et al. An evidence map of systematic reviews on models of outpatient care for patients with chronic heart diseases. Syst Rev. 2023;12(1):80. https:\/\/doi.org\/10.1186\/s13643-023-02227-z.","journal-title":"Syst Rev"},{"issue":"1","key":"744_CR116","doi-asserted-by":"publisher","first-page":"e151870","DOI":"10.5812\/icrj-151870","volume":"18","author":"LG Afra","year":"2024","unstructured":"Afra LG, Mousavi A, Mirzaei M, Rahimi Y, Khosravi F, Rahmanian M, et al. Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review. Int Cardiovasc Res J. 2024;18(1):e151870. https:\/\/doi.org\/10.5812\/icrj-151870.","journal-title":"Int Cardiovasc Res J"},{"issue":"3","key":"744_CR117","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/fjc.0000000000001665","volume":"85","author":"X Chen","year":"2025","unstructured":"Chen X, Xue B, Xu L. Efficacy and safety of treating pulmonary arterial hypertension with imatinib: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2025;85(3):177\u201385. https:\/\/doi.org\/10.1097\/fjc.0000000000001665.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"744_CR118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40256-023-00613-5","volume":"24","author":"OA Nabeh","year":"2024","unstructured":"Nabeh OA, et al. A systematic review of novel therapies of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2024;24(1):39\u201354. https:\/\/doi.org\/10.1007\/s40256-023-00613-5.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"8","key":"744_CR119","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68117","volume":"16","author":"A Rasheed","year":"2024","unstructured":"Rasheed A, et al. New and emerging therapeutic drugs for the treatment of pulmonary arterial hypertension: a systematic review. Cureus. 2024;16(8): e68117. https:\/\/doi.org\/10.7759\/cureus.68117.","journal-title":"Cureus"},{"issue":"3","key":"744_CR120","doi-asserted-by":"publisher","first-page":"258","DOI":"10.5114\/aic.2024.143558","volume":"20","author":"L Xiao","year":"2024","unstructured":"Xiao L, et al. Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis. Postepy Kardiol Interwencyjnej. 2024;20(3):258\u201363. https:\/\/doi.org\/10.5114\/aic.2024.143558.","journal-title":"Postepy Kardiol Interwencyjnej"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00744-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:07:57Z","timestamp":1762528077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00744-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00744-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2025,7,27]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the\n                      Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\n                      \u2014\n                      Brasil\n                      (CAPES)\u2014Finance Code 001. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files). Further information are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the conception and design of the study. RP, FT, and AV planned and designed the study. FT and AV developed search strategies. FD and AV selected potential studies and extracted data from the included studies. AV and FD assessed review quality and reporting. AV and FT performed the statistical analyses. FT and RP conducted the arbitration under disagreement. FT, RP, and AV interpret the results. AV and FT wrote the manuscript, with editing and reviewing contributions from all authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}